Prestige Consumer Healthcare (NYSE:PBH) Price Target Raised to $104.00

Prestige Consumer Healthcare (NYSE:PBH) had its price target hoisted by DA Davidson from $95.00 to $104.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

PBH has been the topic of a number of other research reports. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.50.

Prestige Consumer Healthcare Trading Down 0.4 %

PBH opened at $86.96 on Friday. Prestige Consumer Healthcare has a one year low of $60.00 and a one year high of $88.36. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. The business has a 50 day simple moving average of $79.23 and a two-hundred day simple moving average of $75.48. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 2.43 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insiders Place Their Bets

In other news, insider William P’pool sold 8,987 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mary Beth Fritz sold 9,885 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now owns 18,835 shares of the company’s stock, valued at $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in Prestige Consumer Healthcare by 3.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after acquiring an additional 49,331 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Congress Asset Management Co. raised its stake in shares of Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock worth $70,964,000 after purchasing an additional 43,619 shares during the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after purchasing an additional 252,089 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after buying an additional 33,844 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.